Fermion and Simcere Enter into an Exclusive License and Collaboration Agreement for China's First SSTR4 Agonist Targeting Pain

Contributed by: PR Newswire

Tags

Fermion-Simcere

More Like This

Fermion announces IND Approval of Non-Addictive Pain Relief Drug FZ008-145 by China NMPA

Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor

Fermion's TYK2 JH2 Inhibitor FZ007-119 Granted IND Approval by China NMPA

PR Newswire associated0

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

PR Newswire associated0

Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies

Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain

PR Newswire associated0

Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs

Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain